Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381377798> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4381377798 abstract "Background: The SGLT2 inhibitor dapagliflozin reduces kidney function decline and urine albumin:creatinine ratio (UACR) on a population level. However, there is marked heterogeneity in the efficacy among individual patients. We conducted a decentralized (i.e. at home) N=1 trial to assess the effect of dapagliflozin in individual patients and the feasibility of remote data collection. Methods: Twenty patients with type 2 diabetes, UACR >20 mg/g and eGFR >30 mL/min/1.73m2 entered the randomized placebo-controlled double-blind N=1 trial. Patients were randomly assigned to two periods of 1-week treatment with dapagliflozin 10 mg/day and two periods of 1-week treatment with placebo in random order with 1-week wash-out periods in between. Patients collected and sent their own data with automatic uploading to an online platform and sent early morning urines 5 times/week to the laboratory for albumin and creatinine assessment. Primary outcome was UACR change from baseline (mixed effects model). The study had 80% power to detect a correlation in UACR change between first and second dapagliflozin period of 0.6. Results: Patients had a mean eGFR of 70.2 mL/min/1.73m2 and median UACR of 94.7 mg/g. During the study, dapagliflozin compared to placebo reduced albuminuria by 15.1% (95%CI 3.3 - 28.2; p=0.013). There was a marked variation in the change from baseline in UACR during dapagliflozin treatment periods (range first and second exposure -26.9 to -4.7% and -30.5 to -5.8%, respectively). The individual change in UACR during the first and second exposure correlated in the dapagliflozin periods (r=0.50; p=0.026) but not in the placebo periods (r=0.09; p=0.69). Of all scheduled urine collections (N=816), only 5 collections (0.61%) were not delivered in the laboratory. Conclusion: The individual UACR response to dapagliflozin varies among individual patients and is consistent upon re-exposure. Remote data collection was very reliable with nearly any missed urine collection. Disclosure J.Beernink: None. G.D.Laverman: Advisory Panel; AstraZeneca, Vifor Pharma Management Ltd., Boehringer Ingelheim Inc., Astellas Pharma Inc., Lilly, Other Relationship; Sanofi, AstraZeneca. H.L.Heerspink: Consultant; AstraZeneca, Boehringer Ingelheim International GmbH, Bayer Inc., Eli Lilly and Company, Chinook Therapeutics Inc., CSL Behring, Gilead Sciences, Inc., George Clinical, Merck & Co., Inc., Janssen Research & Development, LLC, Traveere Pharmaceuticals, Novo Nordisk. N.Jongs: Speaker's Bureau; AstraZeneca." @default.
- W4381377798 created "2023-06-21" @default.
- W4381377798 creator A5018701033 @default.
- W4381377798 creator A5038269049 @default.
- W4381377798 creator A5060865001 @default.
- W4381377798 creator A5087013341 @default.
- W4381377798 date "2023-06-20" @default.
- W4381377798 modified "2023-09-27" @default.
- W4381377798 title "884-P: Decentralized N=1 Study—A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin" @default.
- W4381377798 doi "https://doi.org/10.2337/db23-884-p" @default.
- W4381377798 hasPublicationYear "2023" @default.
- W4381377798 type Work @default.
- W4381377798 citedByCount "0" @default.
- W4381377798 crossrefType "journal-article" @default.
- W4381377798 hasAuthorship W4381377798A5018701033 @default.
- W4381377798 hasAuthorship W4381377798A5038269049 @default.
- W4381377798 hasAuthorship W4381377798A5060865001 @default.
- W4381377798 hasAuthorship W4381377798A5087013341 @default.
- W4381377798 hasConcept C126322002 @default.
- W4381377798 hasConcept C126894567 @default.
- W4381377798 hasConcept C134018914 @default.
- W4381377798 hasConcept C142724271 @default.
- W4381377798 hasConcept C159641895 @default.
- W4381377798 hasConcept C19720800 @default.
- W4381377798 hasConcept C204787440 @default.
- W4381377798 hasConcept C27081682 @default.
- W4381377798 hasConcept C2776174234 @default.
- W4381377798 hasConcept C2777180221 @default.
- W4381377798 hasConcept C2777422806 @default.
- W4381377798 hasConcept C2780026642 @default.
- W4381377798 hasConcept C2780306776 @default.
- W4381377798 hasConcept C2908647359 @default.
- W4381377798 hasConcept C555293320 @default.
- W4381377798 hasConcept C71924100 @default.
- W4381377798 hasConcept C99454951 @default.
- W4381377798 hasConceptScore W4381377798C126322002 @default.
- W4381377798 hasConceptScore W4381377798C126894567 @default.
- W4381377798 hasConceptScore W4381377798C134018914 @default.
- W4381377798 hasConceptScore W4381377798C142724271 @default.
- W4381377798 hasConceptScore W4381377798C159641895 @default.
- W4381377798 hasConceptScore W4381377798C19720800 @default.
- W4381377798 hasConceptScore W4381377798C204787440 @default.
- W4381377798 hasConceptScore W4381377798C27081682 @default.
- W4381377798 hasConceptScore W4381377798C2776174234 @default.
- W4381377798 hasConceptScore W4381377798C2777180221 @default.
- W4381377798 hasConceptScore W4381377798C2777422806 @default.
- W4381377798 hasConceptScore W4381377798C2780026642 @default.
- W4381377798 hasConceptScore W4381377798C2780306776 @default.
- W4381377798 hasConceptScore W4381377798C2908647359 @default.
- W4381377798 hasConceptScore W4381377798C555293320 @default.
- W4381377798 hasConceptScore W4381377798C71924100 @default.
- W4381377798 hasConceptScore W4381377798C99454951 @default.
- W4381377798 hasIssue "Supplement_1" @default.
- W4381377798 hasLocation W43813777981 @default.
- W4381377798 hasOpenAccess W4381377798 @default.
- W4381377798 hasPrimaryLocation W43813777981 @default.
- W4381377798 hasRelatedWork W1544023406 @default.
- W4381377798 hasRelatedWork W2046899919 @default.
- W4381377798 hasRelatedWork W2113389249 @default.
- W4381377798 hasRelatedWork W2124955738 @default.
- W4381377798 hasRelatedWork W2274357864 @default.
- W4381377798 hasRelatedWork W3119567526 @default.
- W4381377798 hasRelatedWork W3132812123 @default.
- W4381377798 hasRelatedWork W3154959553 @default.
- W4381377798 hasRelatedWork W393698729 @default.
- W4381377798 hasRelatedWork W656697013 @default.
- W4381377798 hasVolume "72" @default.
- W4381377798 isParatext "false" @default.
- W4381377798 isRetracted "false" @default.
- W4381377798 workType "article" @default.